FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3139249856> ?p ?o ?g. }

• W3139249856 endingPage "677" @default.
• W3139249856 startingPage "674" @default.
• W3139249856 abstract "Systemic light-chain (AL) amyloidosis has a poor prognosis, especially when progressive heart failure occurs. AL treatment has improved and the combination of bortezomib, dexamethasone, and cyclophosphamide had become a widely used treatment regimen, conferring a high response rate and prolonged survival, which could be improved with daratumumab adjunction.1 However therapeutic options are limited in relapsed/refractory (R/R) patients, especially those who progressed after treatment with daratumumab.2 AL amyloidosis is characterized by a frequent t(11;14) translocation, detected in up to 50% of AL patient.3 In myeloma cells, this translocation is also associated with higher BCL2 and lower MCL-1/BAX expression, conferring in vitro sensitivity to BCL2 inhibition with venetoclax.4 These results were subsequently confirmed in a clinical trial on patients with R/R myeloma in which venetoclax showed promising activity, especially in patients harbouring the t(11;14) translocation.5 Given the high rate of t(11;14) in AL amyloidosis, venetoclax could be an attractive treatment option for R/R AL amyloidosis. However, only few cases and a cohort of 12 patients have recently6 been reported, including a limited number of patients with cardiac involvement. We report here the results of a single-centre retrospective study on consecutive R/R AL amyloidosis patients treated off-label with venetoclax in a French academic referral centre between February 2017 and January 2020. The diagnosis of AL amyloidosis and evaluation of organ involvement were established locally according to consensus criteria.7 Cardiac stage was determined using the European Modified Mayo Clinic Stage. The standard and updated criteria for cardiac and haematological response evaluation were used.8 Three patients had associated multiple myeloma (two patients had bone lesions, and one patient had anaemia, renal failure and 56% plasma cells in the bone marrow aspirate). Venetoclax was given daily, alone or in association with dexamethasone, with or without bortezomib. Treatment was administered until progression or toxicity. Patients received prophylaxis based on cotrimoxazole, valaciclovir, and penicillin V. Within the limitations of a retrospective study, tolerability and toxicity data were also collected. Toxicity grading followed Common Terminology Criteria for Adverse Events version 5.0. Data were recorded electronically according to the French CNIL (Commission National de l’ Informatique et des Libertés; authorization number # 1846564 v0, March, 25th 2015). Ten patients with R/R AL amyloidosis were treated with venetoclax. Their clinical characteristics are shown in Table I. The median age was 71 years (40–84). The median number of organs affected was 2 (1–4). Nine (90%) patients had cardiac disease: two patients with stage I, two with stage IIIA, and six with stage IIIB. Six patients had renal involvement and three multiple myeloma. Translocation t(11;14) was detected in seven patients, absent in two, and undetermined in one. The median value for the difference between involved and uninvolved light chains (dFLC) was 90 mg/dl (21–998). Whose CyBorD IMiDs CR VGPR PR SD PD The median number of previous lines was 3 (2–4) and all patients had been treated previously with bortezomib and daratumumab. The best haematological response with daratumumab was as follows: a very good partial response (VGPR) for one patient, a partial response (PR) for five, stable disease (SD) for three and progressive disease (PD) for one patient. The reasons for initiating venetoclax therapy were refractory disease for four patients (40%), relapse for four (40%), and non-optimal haematological response for two (20%). Seven patients received a combination of venetoclax, bortezomib, and dexamethasone, as previously reported for multiple myeloma treatment.9 Two patients received a combination of venetoclax and dexamethasone, and one received venetoclax as a single agent. Patients received a median of 6 (1–21) cycles. Five patients received 400 mg per day, four 200 mg per day, and one 100 mg per day. The median duration of treatment was 189 days (31–1028). At the time of the analysis, four patients were still on treatment and six had stopped (three because of PD and three because of side effects). The overall haematological response rate was 66·6% for the nine patients assessable for haematological response. Three patients achieved a complete response (CR), two a VGPR, and one a PR. Two patient had SD and one PD (Fig 1 and Table SI). Among the seven patients harbouring the t(11;14) translocation, four showed at least a VGPR, while only one of the three patients without t(11;14) experienced a response (VGPR). The median time to reach the best haematological response was 43 days (21–78). Four of the six patients with a haematological response were still on treatment and the median duration of the response was 241 days. The median follow-up was 270·5 days (31–1 028) and 50% of patients were still alive at the time of this report. The median overall survival was 10·5 months (Fig S1). Among the nine patients with cardiac involvement, seven were evaluable for cardiac response. Four patients (57·2%) had a cardiac response, one (14·2%) had SD, and two (28·6%) showed progression of the cardiac dysfunction. Among the six patients with renal involvement, five were evaluable for renal response. One (20%) had a renal response, three (60%) had SD, and one (20%) showed renal progression (Table SI). In terms of safety, grade 1–2 diarrhoea was the most common adverse event (n = 4). Four patients (40%) experienced infectious events, including pneumonia (n = 2), influenza (n = 1), and a urinary tract infection (n = 1). One patient (10%) showed haematological toxicity, with anaemia and grade 3 thrombocytopenia. Three patients discontinued venetoclax due to side effects (grade 3 asthenia, influenza infection, and acute respiratory distress; Table SII). None of the patients experienced tumour lysis syndrome. Adverse events were in line with what we observed with daratumumab in this population,10 reflecting more the fragility of these patients than the treatment toxicity. Five patients (50%) died: three from cardiac complications of amyloidosis, one from infectious complications, and one from an undetermined cause. In conclusion, we report a series of heavily pre-treated R/R cardiac AL amyloidosis patients, most of them with a severe cardiac involvement, treated with venetoclax. This treatment administrated as a single agent or in association with bortezomib and/or dexamethasone resulted in a sustained haematological and cardiac response with acceptable toxicities. These results support the prospective evaluation of venetoclax in AL amyloidosis. FL reports personal fees from Miltenyi and travel grants from Celgene and Jansen. CH reports personal fees from Celgene during the conduct of the study and personal fees from Roche, Amgen, Janssen, Gilead, Novartis, and Takeda outside the submitted work. SO has received honoraria from Pfizer. HP, KB, JD, SO, AG, AL, AM, LR, RG, CG, TD, FLB and FL treated patients and collected data. EP perfomed the pathological review. ABF and VMF performed laboratory tests. HP and FL wrote the manuscript. All the authors read and approved the manuscript. Table SI. Haematological, cardiac, and renal response in evaluable patients treated with venetoclax. ORR, overall response rate; CR, complete response; VGPR, very good partial response PR, partial response; SD stable disease; PD, progressive disease. Table SII. Adverse events reported during treatment with venetoclax, as recorded according to the Common Terminology Criteria for Adverse Events version v5.0. Fig S1. Overall survival, estimated by Kaplan Meier curve, from the time of venetoclax initiation to death. Please note: The publisher is not responsible for the content or functionality of any supporting information supplied by the authors. Any queries (other than missing content) should be directed to the corresponding author for the article." @default.
• W3139249856 created "2021-03-29" @default.
• W3139249856 creator A5007139107 @default.
• W3139249856 creator A5012617867 @default.
• W3139249856 creator A5019631982 @default.
• W3139249856 creator A5026263222 @default.
• W3139249856 creator A5031041032 @default.
• W3139249856 creator A5035135667 @default.
• W3139249856 creator A5037590260 @default.
• W3139249856 creator A5043992495 @default.
• W3139249856 creator A5069447323 @default.
• W3139249856 creator A5070623406 @default.
• W3139249856 creator A5073138736 @default.
• W3139249856 creator A5077217660 @default.
• W3139249856 creator A5078250435 @default.
• W3139249856 creator A5086054912 @default.
• W3139249856 creator A5086219277 @default.
• W3139249856 creator A5089376207 @default.
• W3139249856 date "2021-03-13" @default.
• W3139249856 modified "2023-10-10" @default.
• W3139249856 title "Venetoclax induces profound and sustained responses in patients with relapsed/refractory light‐chain amyloidosis" @default.
• W3139249856 cites W2008110383 @default.
• W3139249856 cites W2050702798 @default.
• W3139249856 cites W2098093182 @default.
• W3139249856 cites W2111080788 @default.
• W3139249856 cites W2746367132 @default.
• W3139249856 cites W2893963168 @default.
• W3139249856 cites W2979520565 @default.
• W3139249856 cites W3014227371 @default.
• W3139249856 cites W3021689191 @default.
• W3139249856 cites W3107319200 @default.
• W3139249856 doi "https://doi.org/10.1111/bjh.17380" @default.
• W3139249856 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/33713427" @default.
• W3139249856 hasPublicationYear "2021" @default.
• W3139249856 type Work @default.
• W3139249856 sameAs 3139249856 @default.
• W3139249856 citedByCount "8" @default.
• W3139249856 countsByYear W31392498562021 @default.
• W3139249856 countsByYear W31392498562022 @default.
• W3139249856 countsByYear W31392498562023 @default.
• W3139249856 crossrefType "journal-article" @default.
• W3139249856 hasAuthorship W3139249856A5007139107 @default.
• W3139249856 hasAuthorship W3139249856A5012617867 @default.
• W3139249856 hasAuthorship W3139249856A5019631982 @default.
• W3139249856 hasAuthorship W3139249856A5026263222 @default.
• W3139249856 hasAuthorship W3139249856A5031041032 @default.
• W3139249856 hasAuthorship W3139249856A5035135667 @default.
• W3139249856 hasAuthorship W3139249856A5037590260 @default.
• W3139249856 hasAuthorship W3139249856A5043992495 @default.
• W3139249856 hasAuthorship W3139249856A5069447323 @default.
• W3139249856 hasAuthorship W3139249856A5070623406 @default.
• W3139249856 hasAuthorship W3139249856A5073138736 @default.
• W3139249856 hasAuthorship W3139249856A5077217660 @default.
• W3139249856 hasAuthorship W3139249856A5078250435 @default.
• W3139249856 hasAuthorship W3139249856A5086054912 @default.
• W3139249856 hasAuthorship W3139249856A5086219277 @default.
• W3139249856 hasAuthorship W3139249856A5089376207 @default.
• W3139249856 hasConcept C126322002 @default.
• W3139249856 hasConcept C142424586 @default.
• W3139249856 hasConcept C143998085 @default.
• W3139249856 hasConcept C159654299 @default.
• W3139249856 hasConcept C203014093 @default.
• W3139249856 hasConcept C2777938653 @default.
• W3139249856 hasConcept C2778461978 @default.
• W3139249856 hasConcept C2779551797 @default.
• W3139249856 hasConcept C2779675984 @default.
• W3139249856 hasConcept C2779951007 @default.
• W3139249856 hasConcept C36394416 @default.
• W3139249856 hasConcept C71924100 @default.
• W3139249856 hasConcept C86803240 @default.
• W3139249856 hasConcept C87355193 @default.
• W3139249856 hasConceptScore W3139249856C126322002 @default.
• W3139249856 hasConceptScore W3139249856C142424586 @default.
• W3139249856 hasConceptScore W3139249856C143998085 @default.
• W3139249856 hasConceptScore W3139249856C159654299 @default.
• W3139249856 hasConceptScore W3139249856C203014093 @default.
• W3139249856 hasConceptScore W3139249856C2777938653 @default.
• W3139249856 hasConceptScore W3139249856C2778461978 @default.
• W3139249856 hasConceptScore W3139249856C2779551797 @default.
• W3139249856 hasConceptScore W3139249856C2779675984 @default.
• W3139249856 hasConceptScore W3139249856C2779951007 @default.
• W3139249856 hasConceptScore W3139249856C36394416 @default.
• W3139249856 hasConceptScore W3139249856C71924100 @default.
• W3139249856 hasConceptScore W3139249856C86803240 @default.
• W3139249856 hasConceptScore W3139249856C87355193 @default.
• W3139249856 hasIssue "3" @default.
• W3139249856 hasLocation W31392498561 @default.
• W3139249856 hasOpenAccess W3139249856 @default.
• W3139249856 hasPrimaryLocation W31392498561 @default.
• W3139249856 hasRelatedWork W154367669 @default.
• W3139249856 hasRelatedWork W206392377 @default.
• W3139249856 hasRelatedWork W2133132479 @default.
• W3139249856 hasRelatedWork W2135322729 @default.
• W3139249856 hasRelatedWork W2766555623 @default.
• W3139249856 hasRelatedWork W2892264640 @default.
• W3139249856 hasRelatedWork W4239236296 @default.
• W3139249856 hasRelatedWork W4283011468 @default.
• W3139249856 hasRelatedWork W4290698720 @default.

• next